GlaxoSmithKline

Recent news

• J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
  TipRanks · 9/14
• GlaxoSmithKline (GSK.US) strengthens its oncology pipeline! Acquires trispecific T-cell engager from Enmabio for up to $750 million, targeting multiple myeloma.
  Zhitong Finance · 9/15
• GSK Target Raised to GBP22.00 From GBP20.00 by Berenberg
  Dow Jones · 9/15
• Hutchmed (00013.HK) announced that it has entered into a licensing agreement with GlaxoSmithKline for a KRAS-EGFR antibody-drug conjugate cancer therapy.
  Gelonghui Finance · 9/3
• Company notice
  6-K: Gsk Enters Agreement to Acquire Idrx, Inc.
  SEC · 1/13
• Company notice
  6-K: Gsk Completes Acquisition of Idrx, Inc.
  SEC · 2/24
• GSK Target Started at GBP19.75 by RBC
  Dow Jones · 9/9
• Company notice
  HENGRUI PHARMA: Inside Information Announcement and Overseas Regulatory Announcement - Entering into Collaboration, Option and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited and GlaxoSmithKline Intellectual Property (No. 4) Limited
  HKEX · 7/28
• J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
  TipRanks · 9/1
• US Stock Market Movements | HUTCHMED (HCM.US) Surges Over 14% on Licensing Agreement with GlaxoSmithKline for Cancer Drug
  Zhitong Finance · 9/3
• TD Cowen Upgrades GlaxoSmithKline(GSK.US) to Buy Rating, Maintains Target Price $70
  Market Newswire · 8/25
• Company notice
  6-K: Tesaro, A Gsk Subsidiary, Initiates Litigation Against Anaptysbio, Inc.
  SEC · 11/21
• Company notice
  Beijing Wantai Biological Pharmacy Enterprise: Announcement from Beijing Wantai Biological Pharmacy Enterprise regarding the termination of the cooperation agreement with GSK by its wholly-owned subsidiary.
  SZSI · 7/23

Headlines are aggregated automatically and are not independently verified or edited by our team.